Connect with us

4 Microchip Stocks to Buy for High-Powered Growth

The best microchip stocks are profiting on chip shortages. These companies have plenty of room to expand their sales and profits for investors.
The post 4 Microchip Stocks to Buy for High-Powered Growth appeared first on Investment U.

Published

on

Space exploration, artificial intelligence and the metaverse. These are just three of the most interesting technological frontiers that exist today. And they all require advanced microchips to function. That’s why I’m sharing some of the best microchip stocks below.

Within each of these industries, there are big stock trades that you could make. However, there’s also one thing that all three of these frontiers have in common.

For microchip companies, it doesn’t matter if humans ever make it to Mars or create the metaverse. That’s because microchip companies are going to earn money regardless of whether or not these ventures are successful. Fail or succeed, they’re happy to sell Elon Musk and Mark Zuckerberg the microchips to help them try. In this sense, microchip companies are essentially selling pickaxes to gold diggers.

Microchips are also used in much more than just cutting-edge technology. Even though you never see them, microchips are working behind the scenes to power the world that you live in. As you read this a microchip is powering the computer or phone that you’re using. Even something as simple as watching Stranger Things on Netflix requires a couple of microchips.

For these reasons and more, many investors feel that they should include at least one microchip stock in their portfolio. If you’ve been contemplating buying, I’ve selected four that you should consider.

Let’s take a look at four of the best microchip stocks to buy.

Microchip Stocks to Buy

Note: I’m not a financial advisor and am just offering my own research and commentary. Please do your own due diligence before making any investment decisions.

Once you’re done with the list below, you might be interested in these top metaverse stocks next.

Hottest Microchip Stock: Advanced Micro Devices

Advanced Micro Devices (Nasdaq: AMD) is an American semiconductor company based in Santa Clara, CA. It develops computer processors for both business and consumer markets.

So far in 2021, AMD’s stock is up close to 50%. It is also up an astounding 1,900% over the past five years. With this type of return, it’s easy to ask whether the ship has sailed for AMD. Also, we know that past returns are no predictor of future performance. However, according to AMD’s latest earnings release, it doesn’t look like it’s slowing down anytime soon.

In Q3 2021, AMD reported record revenue of $4.3 billion, up 54% YoY. It also posted a net income of $923 million, up 136% YoY. What’s impressive is that these numbers are compared to 2020, which was also a record year for AMD. In 2020, AMD posted annual revenue of $9.76 billion and a net income of $2.49 billion. Both of these numbers were annual records. So far through 2021, AMD is set to blow these 2020 records away.

One thing that has helped AMD succeed in the past year or so is how quickly it started prepping its supply chain during the COVID-19 pandemic. AMD’s Chief Technology Officer Mark Papermaster stated, “Everybody has had to increase their focus on the supply chain but we did so from the very beginning of the pandemic.”

In terms of the global chip shortage, there are two other factors that have protected AMD. First, it focuses on more advanced chips which are less affected than mass-produced older chips. Also, AMD focuses on high-margin chips. This allows it to channel resources while also increasing its revenue.

Due to its recent earnings report, Advanced Micro Devices is currently one of the hottest microchip stocks to buy. However, the best microchip stock to buy for growth falls with another company.

Best Microchip Stock for Growth: Nvidia

Note: I own a small position in Nvidia 

Nvidia (Nasdaq: NVDA) is another incredibly exciting microchip stock. It focuses on graphics processing units that are used for gaming, mobile computing and automotive markets.

In 2021, Nvidia posted annual revenue of $16.68 billion as well as a net income of $4.33 billion. These numbers were up 52% and 54% respectively. This strong performance is just part of the reason why its stock has surged over 100% in 2021.

Nvidia’s chips are incredibly powerful and are currently used in 342 of the world’s top 500 supercomputers (68%). In particular, Nvidia has a hand in powering autonomous vehicles and augmented reality. Notably, it works closely with Tesla. Tesla’s in-house supercomputer uses 5,000 Nvidia A100 GPUs.

Autonomous vehicles and augmented reality are two exciting up-and-coming industries. Check out these top augmented reality stocks. Over the next few decades, these industries should eventually play a critical role in society. This is why Nvidia was selected as the best microchip stock for growth.

Nvidia’s stock is up over 1,300% over the past five years.

Best Microchip Stock for Dividends: Intel

Out of all the microchip stocks to buy, Intel (Nasdaq: INTC) is the industry dinosaur. I mean this as a compliment. Intel was founded in 1968 and was instrumental in developing personal computers as we know them.

In 2020, Intel generated over $77 billion in revenue and a net income of close to $21 billion. Intel has experienced modest revenue growth of 7.13% on average over the past five years. This isn’t bad for a company of its size. However, it’s safe to say that Intel’s days of rapid growth are behind it. That said, it still may be one of the best microchip stocks for dividends.

Intel currently has a dividend yield of around 2.8%. The quarterly dividend payment is about $0.35 per share. Despite the current chip shortage and aftermath of COVID-19, Intel has stated that it’s committed to paying its dividend.

Intel’s stock is about breakeven year-to-date and is up close to 50% in the past five years.

Finally, let’s take a look at the best overall when it comes to microchip stocks…

Best Overall Microchip Stock: TSMC

When it comes to producing microchips, most companies focus on only one part of the process. Some companies design the chips while others actually manufacture them. A company that focuses only on manufacturing is known as a pure-play semiconductor foundry. Taiwan Semiconductor Manufacturing (NYSE: TSM) is currently the world’s largest pure-play semiconductor foundry. It also ranks 11th on the list of the world’s largest companies by market capitalization.

The company was founded in 1987 and has a long history of ramping up production. Since 1994, it has delivered a CAGR of 17.4% in revenue and 16.1% in earnings. In 2020, TSM brought in $1.34 trillion (TWD) as well as $517.89 billion in net income.

TSM’s stock is up just 5% so far in 2021 but is up close to 300% over the past five years.

What’s currently exciting about TSM is that it has plans to open up a $12 billion new mega factory in Pheonix, Arizona. Over the next 10-15 years, it plans to build as many as six factories in Arizona. TSM is a little similar to Intel in that it’s already an immense company whose growth is mainly behind it. However, TSM is also in an incredibly unique position right now.

Due to COVID-19, supply chain issues and rising demand, the world is experiencing a global chip shortage. TSM was already one of the world’s biggest manufacturers of microchips. However, now it’s has taken center stage in the global supply chain.

Many different industries are waiting with checkbooks at the ready for TSM to ramp up its production. With aggressive expansion plans already in motion, TSM seems on the right path to capitalize on the situation.

TSM has great potential for growth as well as a solid dividend payment. For this reason, it’s considered one of the best overall microchip stocks.

I hope that you’ve found this article valuable when it comes to learning four high-powered microchip stocks to buy. As usual, all investment decisions should be based on your own due diligence and risk tolerance.

If you’re looking for more trends to invest in, sign up for Profit Trends below. It’s a free e-letter that’s packed with tips and tricks. You’ll hear from investing experts on the top trending opportunities.

The post 4 Microchip Stocks to Buy for High-Powered Growth appeared first on Investment U.

Read More

Continue Reading

Uncategorized

Pharma industry reputation remains steady at a ‘new normal’ after Covid, Harris Poll finds

The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45%…

Published

on

The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45% of US respondents in 2023, according to the latest Harris Poll data. That’s exactly the same as the previous year.

Pharma’s highest point was in February 2021 — as Covid vaccines began to roll out — with a 62% positive US perception, and helping the industry land at an average 55% positive sentiment at the end of the year in Harris’ 2021 annual assessment of industries. The pharma industry’s reputation hit its most recent low at 32% in 2019, but it had hovered around 30% for more than a decade prior.

Rob Jekielek

“Pharma has sustained a lot of the gains, now basically one and half times higher than pre-Covid,” said Harris Poll managing director Rob Jekielek. “There is a question mark around how sustained it will be, but right now it feels like a new normal.”

The Harris survey spans 11 global markets and covers 13 industries. Pharma perception is even better abroad, with an average 58% of respondents notching favorable sentiments in 2023, just a slight slip from 60% in each of the two previous years.

Pharma’s solid global reputation puts it in the middle of the pack among international industries, ranking higher than government at 37% positive, insurance at 48%, financial services at 51% and health insurance at 52%. Pharma ranks just behind automotive (62%), manufacturing (63%) and consumer products (63%), although it lags behind leading industries like tech at 75% positive in the first spot, followed by grocery at 67%.

The bright spotlight on the pharma industry during Covid vaccine and drug development boosted its reputation, but Jekielek said there’s maybe an argument to be made that pharma is continuing to develop innovative drugs outside that spotlight.

“When you look at pharma reputation during Covid, you have clear sense of a very dynamic industry working very quickly and getting therapies and products to market. If you’re looking at things happening now, you could argue that pharma still probably doesn’t get enough credit for its advances, for example, in oncology treatments,” he said.

Read More

Continue Reading

Spread & Containment

I created a ‘cosy game’ – and learned how they can change players’ lives

Cosy, personal games, as I discovered, can change the lives of the people who make them and those who play them.

Published

on

By

Cosy games exploded in popularity during the pandemic. Takoyaki Tech/Shutterstock

The COVID pandemic transformed our lives in ways many of us are still experiencing, four years later. One of these changes was the significant uptake in gaming as a hobby, chief among them being “cosy games” like Animal Crossing: New Horizons (2020).

Players sought comfort in these wholesome virtual worlds, many of which allowed them to socialise from the safety of their homes. Cosy games, with their comforting atmospheres, absence of winning or losing, simple gameplay, and often heartwarming storylines provided a perfect entry point for a new hobby. They also offered predictability and certainty at a time when there wasn’t much to go around.

Cosy games are often made by small, independent developers. “Indie games” have long been evangelised as the purest form of game development – something anyone can do, given enough perseverance. This means they can provide an entry point for creators who hadn’t made games before, but were nevertheless interested in it, enabling a new array of diverse voices and stories to be heard.

In May 2020, near the start of the pandemic, the small poetry game A Solitary Spacecraft, which was about its developer’s experience of their first few months in lockdown, was lauded as particularly poignant. Such games showcase a potential angle for effective cosy game development: a personal one.

Personal themes are often explored through cosy games. For instance, Chicory and Venba (both released in 2023) tackle difficult topics like depression and immigration, despite their gorgeous aesthetics. This showcases the diversity of experiences on display within the medium.

However, as the world emerges from the pandemic’s shadow, the games industry is facing significant challenges. Economic downturns and acquisitions have caused large layoffs across the sector.

Historically, restructurings like these, or discontent with working conditions, have led talented laid-off developers to create their own companies and explore indie development. In the wake of the pandemic and the cosy game boom, these developers may have more personal stories to tell.

Making my own cosy game

I developed my own cosy and personal game during the pandemic and quickly discovered that creating these games in a post-lockdown landscape is no mean feat.

What We Take With Us (2023) merges reality and gameplay across various digital formats: a website, a Discord server that housed an online alternate reality game and a physical escape room. I created the game during the pandemic as a way to reflect on my journey through it, told through the videos of game character Ana Kirlitz.

The trailer for my game, What We Take With Us.

Players would follow in Ana’s footsteps by completing a series of ten tasks in their real-world space, all centred on improving wellbeing – something I and many others desperately needed during the pandemic.

But creating What We Take With Us was far from straightforward. There were pandemic hurdles like creating a physical space for an escape room amid social distancing guidelines. And, of course, the emotional difficulties of wrestling with my pandemic journey through the game’s narrative.

The release fared poorly, and the game only garnered a small player base – a problem emblematic of the modern games industry.

These struggles were starkly contrasted by the feedback I received from players who played the game, however.

This is a crucial lesson for indie developers: the creator’s journey and the player’s experience are often worlds apart. Cosy, personal games, as I discovered, can change the lives of those who play them, no matter how few they reach. They can fundamentally change the way we think about games, allow us to reconnect with old friends, or even inspire us to change careers – all real player stories.

Lessons in cosy game development

I learned so much about how cosy game development can be made more sustainable for creators navigating the precarious post-lockdown landscape. This is my advice for other creators.

First, collaboration is key. Even though many cosy or personal games (like Stardew Valley) are made by solo creators, having a team can help share the often emotional load. Making games can be taxing, so practising self-care and establishing team-wide support protocols is crucial. Share your successes and failures with other developers and players. Fostering a supportive community is key to success in the indie game landscape.

Second, remember that your game, however personal, is a product – not a reflection of you or your team. Making this distinction will help you manage expectations and cope with feedback.

Third, while deeply considering your audience may seem antithetical to personal projects, your game will ultimately be played by others. Understanding them will help you make better games.

The pandemic reignited the interest in cosy games, but subsequent industry-wide troubles may change games, and the way we make them, forever. Understanding how we make game creation more sustainable in a post-lockdown, post-layoff world is critical for developers and players alike.

For developers, it’s a reminder that their stories, no matter how harrowing, can still meaningfully connect with people. For players, it’s an invitation to embrace the potential for games to tell such stories, fostering empathy and understanding in a world that greatly needs it.


Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.


Adam Jerrett does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

Government

The SNF Institute for Global Infectious Disease Research announces new advisory board

From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in…

Published

on

From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.

Credit: Lori Chertoff/The Rockefeller University

From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.

This international advisory board was created in part to give guidance on how to best use SNFiRU’s resources, as well as bring forward innovative ideas concerning new avenues of research, public education, community engagement, and partnership projects.

SNFiRU was established to strengthen readiness for and response to future health crises, building on the scientific advances and international collaborations forged in the context of the COVID-19 pandemic. Launched with a $75 million grant from the Stavros Niarchos Foundation (SNF) as part of its Global Health Initiative (GHI), the institute provides a framework for international scientific collaboration to foster research innovations and turn them into practical health benefits.

SNFiRU’s mission is to better understand the agents that cause infectious disease and to lower barriers to treatment and prevention globally. To speed this work, the institute launched numerous initiatives in its inaugural year. For instance, SNFiRU awarded 31 research projects in 29 different Rockefeller laboratories for over $5 million to help get collaborative new research efforts off the ground. SNFiRU also supports the Rockefeller University Hospital, where clinical studies are conducted, and brought on board its first physician-scientist through Rockefeller’s Clinical Scholars program. “One of the surprises was the scope of interest from Rockefeller scientists in using their talents to tackle important infectious disease problems,” says Charles M. Rice, Maurice R. and Corinne P. Greenberg Professor in Virology at Rockefeller and director of SNFiRU. “The research topics range from the biology of infectious agents to the dynamics of the immune response to pathogens, and also include a number of infectious disease-adjacent studies.”

In the past 12 months, SNFiRU often brought together scientists studying different aspects of infectious disease as a way to spur new collaborations. In addition to hosting its first annual day-long symposium, SNFiRU initiated a Young Scientist Forum for students and post-doctoral fellows to meet regularly, facilitating cross-laboratory thinking. A bimonthly seminar series has also been established on campus.

Another aim of SNFiRU is to develop relationships with community-based organizations, as well as design and participate in community-engaged research, with a focus on low-income and minority communities. To that end, SNFiRU is helping develop a research project on Chagas disease, a tropical parasitic infection prevalent in Latin America that can cause congestive heart failure and gastrointestinal complications if left untreated. The project will bring together clinicians practicing at health centers in New York, Florida, Texas, and California and basic scientists from multiple institutions to help the communities that are most impacted.

“The SNFiRU international advisory board convenes globally recognized leaders with distinguished biomedical expertise, unrivalled experience in pandemic preparedness and response, and a shared commitment to translating scientific advancements into equitably distributed benefits in real-world settings,” says SNF Co-President Andreas Dracopoulos. “The advisory board will advance the institute’s indispensable mission, which SNF is proud to support as a key part of our Global Health Initiative, and we look forward to seeing breakthroughs in the lab drive better outcomes in lives around the globe.”

The new advisory board will hold its first meeting on April 11th, 2024, following the second annual SNF Institute for Global Infectious Disease Research Symposium at Rockefeller.

Its members are: Rafi Ahmed of Emory University School of Medicine, Cori Bargmann of The Rockefeller University, Yasmin Belkaid of the Pasteur Institute, Anthony S. Fauci, the former director of the National Institute of Allergy and Infectious Diseases, Peter Hotez of Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development, Esper Kallas of of the Butantan Institute, Sharon Lewin of the University of Melbourne Doherty Institue, Carl Nathan of Weill Cornell Medicine, Rino Rappuoli of Fondazione Biotecnopolo di Siena and University of Siena, and Herbert “Skip” Virgin of Washington University School of Medicine and UT Southwestern Medical Center.


Read More

Continue Reading

Trending